{"id":"W2757427979","doi":"10.1200/jco.2017.35.15_suppl.9504","title":"Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Discontinuation; Medicine; Pembrolizumab; Population; Ipilimumab; Internal medicine; Family medicine; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001485619,0.0003867589,0.000651221,0.0002097689,0.0004050945,0.0007047965,0.000306727,0.0007238214,0.001387176],"category_scores_gemma":[0.000911316,0.0002324706,0.001073587,0.0003308951,0.0002785616,0.0006815246,0.0004258363,0.001395039,0.0003889355],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005684648,"about_ca_system_score_gemma":0.0004455366,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004572651,"about_ca_topic_score_gemma":0.0009505308,"domain_scores_codex":[0.999689,0.000117683,0.00002659467,0.00006221943,0.0000395873,0.00006495793],"domain_scores_gemma":[0.9991506,0.0001043231,0.0003094003,0.00005823309,0.00005572976,0.0003216726],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3842247,0.009927517,0.4988603,0.0009392754,0.006073997,0.0009111782,0.0003735555,0.003261582,0.01627685,0.0002096296,0.007617254,0.0713241],"study_design_scores_gemma":[0.04193828,0.1834623,0.7581664,0.0001936991,0.003966897,0.001474395,0.0002220699,0.002330185,0.002748216,0.0003233537,0.00510903,0.00006520163],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957949,0.002062694,0.0001973707,0.0001365516,0.00003669226,0.000141974,0.001004554,0.000009768598,0.0006155437],"genre_scores_gemma":[0.996185,0.000540781,0.0001657263,0.0003009296,0.00007262038,0.0001851604,0.001951731,0.000003736782,0.0005942764],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001485619,"threshold_uncertainty_score":0.007856786,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1240299827595494,"score_gpt":0.4848306160490523,"score_spread":0.3608006332895029,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}